TORONTO, Jan. 20 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) announced that at its special meeting of shareholders held earlier today, shareholders overwhelmingly approved the previously announced sale of Spectral's rapid cardiac immunoassay test business to Nanogen, Inc., voting 99.9% in favour. The transaction is expected to close in due course and remains subject to other customary closing conditions. About Spectral Diagnostics, Inc. -------------------------------- Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral's common shares are listed on The Toronto Stock Exchange: SDI. For additional information please visit Spectral's website at www.spectraldx.com. Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. %SEDAR: 00002006E